SCHEMBL31172742

SCHEMBL31172742

O=C(Oc1c(F)c(F)c(F)c(F)c1F)c1ccc(Cn2cccn2)c(C2CC2)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ KAT7 O95251 3/20 0.33
▸ KAT6A Q92794 3/20 0.33
▸ HTT P42858 2/20 0.33
▸ KLKB1 P03952 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ KAT6B Q8WYB5 2/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HRH3 Q9Y5N1 3/20 0.33
▸ CNR1 P21554 1/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172702 0.87 KMT2A (0.40) ALDH1A1MAPTBRD4MEN1KMT2A
SCHEMBL31172590 0.84 KLKB1 (0.41) MAPTBRD4MEN1KMT2AKAT7
SCHEMBL31172751 0.83 KAT7 (0.37) MAPTBRD4MEN1KMT2AKAT7
SCHEMBL31172591 0.82 HTT (0.44) ALDH1A1MAPTBRD4MEN1KMT2A
SCHEMBL31172623 0.82 BRD4 (0.36) BRD4MEN1KMT2AKAT7KAT6A
SCHEMBL31172826 0.82 THRB (0.39) ALDH1A1BRD4MEN1KMT2AKAT7
SCHEMBL31172689 0.82 KDM4E (0.39) ALDH1A1BRD4MEN1KMT2AKAT7
SCHEMBL31172622 0.81 CNR1 (0.36) ALDH1A1MAPTBRD4MEN1KMT2A
SCHEMBL31172624 0.81 CNR1 (0.36) ALDH1A1MAPTBRD4MEN1KMT2A
SCHEMBL31172606 0.72 GAA (0.49) ALDH1A1MAPTBRD4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B ALDH1A1 2242/4885MAPT 2500/4885BRD4 426/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B ALDH1A1 2242/4885MAPT 2500/4885BRD4 426/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B ALDH1A1 1068/4885MAPT 3581/4885BRD4 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback